We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership.
- Authors
Snyder, Rebecca A; Burtness, Barbara; Cho, May; Rivero, Jaydira Del; Doroshow, Deborah B; Hitchcock, Kathryn E; Kalyan, Aparna; Kim, Christina A; Lukovic, Jelena; Parikh, Aparna R; Sanford, Nina N; Singh, Bhuminder; Shen, Chan; Shroff, Rachna T; Vijayvergia, Namrata; Goodman, Karyn A; Kunz, Pamela L
- Abstract
Many multicenter randomized clinical trials in oncology are conducted through the National Clinical Trials Network (NCTN), an organization consisting of 5 cooperative groups. These groups are made up of multidisciplinary investigators who work collaboratively to conduct trials that test novel therapies and establish best practice for cancer care. Unfortunately, disparities in clinical trial leadership are evident. To examine the current state of diversity, equity, and inclusion across the NCTN, an independent NCTN Task Force for Diversity in Gastrointestinal Oncology was established in 2021, the efforts of which serve as the platform for this commentary. The task force sought to assess existing data on demographics and policies across NCTN groups. Differences in infrastructure and policies were identified across groups as well as a general lack of data regarding the composition of group membership and leadership. In the context of growing momentum around diversity, equity, and inclusion in cancer research, the National Cancer Institute established the Equity and Inclusion Program, which is working to establish benchmark data regarding diversity of representation within the NCTN groups. Pending these data, additional efforts are recommended to address diversity within the NCTN, including standardizing membership, leadership, and publication processes; ensuring diversity of representation across scientific and steering committees; and providing mentorship and training opportunities for women and individuals from underrepresented groups. Intentional and focused efforts are necessary to ensure diversity in clinical trial leadership and to encourage design of trials that are inclusive and representative of the broad population of patients with cancer in the United States.
- Subjects
UNITED States; CLINICAL trials; LEADERSHIP; INFRASTRUCTURE policy; TASK forces
- Publication
JNCI: Journal of the National Cancer Institute, 2023, Vol 115, Issue 10, p1132
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djad121